Smith & Nephew raises 2019 sales target after strong start to year

By Hull Daily Mail | Posted: 3 May 2019

Smith & Nephew sales were up more than four per cent in the first three months of 2019 as the Hull FTSE giant raised its guidance for the year.

The medical equipment manufacturer recorded revenues of $1.2bn in the first quarter, in what was its best quarter in three years.

Smith & Nephew’ boss said a string of clever acquisitions – including a deal to buy US medicine firm Osiris Therapeutics for more than £500m – had put the company in a strong position looking ahead.

Namal Nawana, CEO, said: “It’s been a good start to 2019 across the whole of Smith & Nephew.

“All three global franchises delivered improved organic growth as we continued to improve execution; important confirmation that each has the potential to perform sustainably at or above their markets.

“At the same time, we’ve made well-judged acquisitions that bring in new technologies to strengthen leadership positions across the business, which we expect to further accelerate growth over time.

Smith and Nephew CEO, Namal Nawana

“While recognising that further work remains to achieve the full potential of our portfolio, we are encouraged with our progress towards sustainably delivering above-market growth.”

Underlying sales in the first three months of 2019 hit $1.2bn – up 4.4 per cent on the same period last year.

It was also Smith & Nephew’s highest quarter for sales since 2015.

Read more: Smith & Nephew: Who they are, what they do and where they're from

The company enjoyed strong growth in its emerging markets, led by China, but also cited its string of high-profile purchases.

Smith & Nephew has hit the headlines several times this year for its acquisitions, perhaps most notably its £500m deal to buy Osiris.

Smith & Nephew's NAVIO surgical gadget (Smith & Nephew)

Other big deals include the acquisition of Ceterix Orthopaedics, Leaf Healthcare and Brainlab Orthopaedic Joint Reconstruction.

Speaking about the deal with Osiris, Peter Friedli, chairman and co-founder, said: “I am immensely proud of the business we have built from our research into advanced regenerative technologies.

“Smith & Nephew is the best new owner to take these products forward, widening access to more customers and restoring quality of life for more patients.”

Read more: Smith & Nephew acquires Leaf Healthcare as 2019 buying spree continues

Smith & Nephew’s strong performance at the start of 2019 has led to the FTSE manufacturer increasing its full guidance for the year.

It has now said expected revenue growth will be closer to 3.5 per cent than it previously forecast.

Its expected trading profit margin however remained unchanged, with a range of 22.8 per cent to 23.2 per cent.

Follow us on Facebook and Twitter

Manufacturing News

Source article:

Share Article

Grimsby News

300m South Humber Bank power station given the go-ahead

Hull & East Riding News

New jobs created as construction firm Integra joins 500m scheme

Scunthorpe News

Humberside Airport owner files for bankruptcy in US

Your News

Would you want your employees working from home? Read more in our Your News special report